BETHLEHEM, Pa., Sept. 13, 2011 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Edward L. Erickson, president and CEO of Saladax, will be presenting at the Annual UBS Global Life Sciences Conference at the Grand Hyatt New York in New York City on Tuesday, September 20, 2011 at 12:30 p.m. EDT. The company will also be available for one-on-one meetings during the day. The management presentation will include an overview of the company's business strategy, commercialization progress, products, strategic alliances and development pipeline.
The UBS Global Life Sciences Conference is among the largest healthcare investor conferences in the world. Senior executives from the leading pharmaceutical, biotechnology and medical technology companies will provide their insight and outlook on the global life sciences industry.
About Saladax Biomedical, Inc.
Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics. The Company's dose management technology enables physicians to optimize drug dosing to meet individual patient needs, leading to improved response and quality of life. The Company's 15 MyCare™ dose management assays are comprised of proprietary, automated and cost-effective in vitro diagnostic tests, with a principal focus in oncology. The first MyCare assay available is for one of the most common anticancer drugs, 5-fluorouracil (5-FU). This assay is sold by Saladax in Europe as a CE-marked product and will be distributed in Japan by FALCO biosystems. In the United States and Canada, Myriad Genetic Laboratories, Inc. provides testing for 5-FU dose optimization under the trademark OnDose® through a license to Saladax proprietary technology. Saladax also works with pharmaceutical companies to develop companion diagnostics to provide important clinical information to assist in developing and administering new and existing compounds. For more information, visit www.saladax.com, or follow us on Twitter at https://twitter.com/Saladax.
Saladax Biomedical, Inc.
Edward L. Erickson
President and Chief Executive Officer
SOURCE Saladax Biomedical, Inc.